🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 18 of 28

  1. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  2. LY3484356

    Eli Lilly and Company

    Breast Neoplasms

    phase 1 small molecule active

    1 trial

  3. Larotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 1 small molecule active

    1 trial

  4. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  5. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  6. Letrozole

    Context Therapeutics

    Metastatic Breast Cancer

    phase 1 small molecule terminated

    1 trial

  7. Lifileucel (LN-144)

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 1 mab active

    1 trial

  8. Lifileucel (LN-144/LN-145)

    Iovance Biotherapeutics B.V.

    Uveal Melanoma

    phase 1 mab active

    1 trial

  9. Lifirafenib

    BEONE MEDICINES AUS PTY LTD

    Solid Tumor, Adult

    phase 1 small molecule completed

    1 trial

  10. Linperlisib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  11. Lipegfilgrastim

    Teva Pharma GmbH

    Ewing Family of Tumors, Rhabdomyosarcoma

    phase 1 small molecule completed

    1 trial

  12. Liposomal Mitoxantrone Hydrochloride dose level 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  13. Lipotecan

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  14. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  15. Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  16. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  17. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial

  18. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  19. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

  20. Low Dose MSH2-/- tumor cell vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    pMMR/MSS Advanced Colorectal Cancer

    phase 1 mab active

    1 trial

  21. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive Stage Lung Small Cell Carcinoma

    phase 1 small molecule active

    1 trial

  22. Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

  23. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  24. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  25. M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  26. MC-1-50

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia, in Relapse

    phase 1 mab active

    1 trial

  27. MC-1-50

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 1 mab active

    1 trial

  28. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  29. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  30. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  31. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  32. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  33. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  34. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  35. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  36. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  37. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  38. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  39. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  40. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  41. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  42. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  43. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  44. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  45. MTL-CEBPA

    Hospital Authority, Hong Kong

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  46. MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  47. Mammaglobin-A DNA Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 mab active

    1 trial

  48. Marijuana via vape device

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking-Related Carcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.